576 related articles for article (PubMed ID: 11736864)
1. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A).
Palmer JL; Scott RJ; Gibson A; Dickins M; Pleasance S
Br J Clin Pharmacol; 2001 Nov; 52(5):555-61. PubMed ID: 11736864
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1.
Blakey GE; Lockton JA; Perrett J; Norwood P; Russell M; Aherne Z; Plume J
Br J Clin Pharmacol; 2004 Feb; 57(2):162-9. PubMed ID: 14748815
[TBL] [Abstract][Full Text] [Related]
3. Assessment of cytochrome P450 activity by a five-drug cocktail approach.
Zhu B; Ou-Yang DS; Chen XP; Huang SL; Tan ZR; He N; Zhou HH
Clin Pharmacol Ther; 2001 Nov; 70(5):455-61. PubMed ID: 11719732
[TBL] [Abstract][Full Text] [Related]
4. Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects.
Chen XP; Tan ZR; Huang SL; Huang Z; Ou-Yang DS; Zhou HH
Clin Pharmacol Ther; 2003 Mar; 73(3):264-71. PubMed ID: 12621391
[TBL] [Abstract][Full Text] [Related]
5. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
6. Activity of CYP2E1 and CYP3A enzymes in adults with moderate alcohol consumption: a comparison with nonalcoholics.
Liangpunsakul S; Kolwankar D; Pinto A; Gorski JC; Hall SD; Chalasani N
Hepatology; 2005 May; 41(5):1144-50. PubMed ID: 15841467
[TBL] [Abstract][Full Text] [Related]
7. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects.
Frye RF; Branch RA
Br J Clin Pharmacol; 2002 Feb; 53(2):155-62. PubMed ID: 11851639
[TBL] [Abstract][Full Text] [Related]
8. Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects.
Asimus S; Elsherbiny D; Hai TN; Jansson B; Huong NV; Petzold MG; Simonsson US; Ashton M
Fundam Clin Pharmacol; 2007 Jun; 21(3):307-16. PubMed ID: 17521300
[TBL] [Abstract][Full Text] [Related]
9. Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes.
Frye RF; Matzke GR; Adedoyin A; Porter JA; Branch RA
Clin Pharmacol Ther; 1997 Oct; 62(4):365-76. PubMed ID: 9357387
[TBL] [Abstract][Full Text] [Related]
10. Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers.
Krupka E; Venisse N; Lafay C; Gendre D; Diquet B; Bouquet S; Perault MC
Eur J Clin Pharmacol; 2006 Aug; 62(8):653-9. PubMed ID: 16832678
[TBL] [Abstract][Full Text] [Related]
11. Liver disease selectively modulates cytochrome P450--mediated metabolism.
Frye RF; Zgheib NK; Matzke GR; Chaves-Gnecco D; Rabinovitz M; Shaikh OS; Branch RA
Clin Pharmacol Ther; 2006 Sep; 80(3):235-45. PubMed ID: 16952490
[TBL] [Abstract][Full Text] [Related]
12. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.
Turpault S; Brian W; Van Horn R; Santoni A; Poitiers F; Donazzolo Y; Boulenc X
Br J Clin Pharmacol; 2009 Dec; 68(6):928-35. PubMed ID: 20002088
[TBL] [Abstract][Full Text] [Related]
14. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
Yeh RF; Gaver VE; Patterson KB; Rezk NL; Baxter-Meheux F; Blake MJ; Eron JJ; Klein CE; Rublein JC; Kashuba AD
J Acquir Immune Defic Syndr; 2006 May; 42(1):52-60. PubMed ID: 16639344
[TBL] [Abstract][Full Text] [Related]
15. Validation of incorporating flurbiprofen into the Pittsburgh cocktail.
Zgheib NK; Frye RF; Tracy TS; Romkes M; Branch RA
Clin Pharmacol Ther; 2006 Sep; 80(3):257-63. PubMed ID: 16952492
[TBL] [Abstract][Full Text] [Related]
16. Determination of a 'GW cocktail' of cytochrome P450 probe substrates and their metabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry.
Scott RJ; Palmer J; Lewis IA; Pleasance S
Rapid Commun Mass Spectrom; 1999; 13(23):2305-19. PubMed ID: 10567928
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses.
Hohmann N; Blank A; Burhenne J; Suzuki Y; Mikus G; Haefeli WE
Br J Clin Pharmacol; 2019 Oct; 85(10):2310-2320. PubMed ID: 31222796
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 2E1 and 3A activities do not differ between Mexicans and European Americans.
Poland RA; Lin KM; Nuccio C; Wilkinson GR
Clin Pharmacol Ther; 2002 Sep; 72(3):288-93. PubMed ID: 12235449
[TBL] [Abstract][Full Text] [Related]
19. Single plasma sampling to predict oral clearance of CYP3A probe midazolam.
Zhu B; Ou-Yang DS; Cheng ZN; Huang SL; Zhou HH
Acta Pharmacol Sin; 2001 Jul; 22(7):634-8. PubMed ID: 11749829
[TBL] [Abstract][Full Text] [Related]
20. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.
Wang Z; Gorski JC; Hamman MA; Huang SM; Lesko LJ; Hall SD
Clin Pharmacol Ther; 2001 Oct; 70(4):317-26. PubMed ID: 11673747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
